These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 2584703)

  • 1. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
    Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
    J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
    Sykes M; Sheard M; Sachs DH
    J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M; Bukhari Z; Sachs DH
    Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M; Sharabi Y; Sachs DH
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
    Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
    J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
    Colson YL; Zadach K; Nalesnik M; Ildstad ST
    Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
    Sykes M; Eisenthal A; Sachs DH
    J Immunol; 1988 May; 140(9):2903-11. PubMed ID: 2966200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloengraftment in IL-2-treated mice.
    Sykes M; Pearson DA
    Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
    Hummel S; Wilms D; Vitacolonna M; Zöller M
    J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.
    Chester CH; Sykes M; Sachs DH
    Bone Marrow Transplant; 1989 Mar; 4(2):195-200. PubMed ID: 2650790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
    Sykes M
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():30-3. PubMed ID: 2534057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
    Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
    J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.